[
  {
    "ts": null,
    "headline": "Study showed MiniMed™ 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus",
    "summary": "A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)— even on days when mealtime boluses were missed. CareLink™ data showed that the studied user population achieved 76.3% TIR on missed bolus days when using SmartGuard™ technology with recommended optimal settings (100 mg/dL glucose target; two-hour active insulin time). The study investigated off-lab",
    "url": "https://finnhub.io/api/news?id=903017c04ca26ead4bd3f207b6bee76879d74defea2c5244961ea489dee1fdc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767794640,
      "headline": "Study showed MiniMed™ 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus",
      "id": 138027254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)— even on days when mealtime boluses were missed. CareLink™ data showed that the studied user population achieved 76.3% TIR on missed bolus days when using SmartGuard™ technology with recommended optimal settings (100 mg/dL glucose target; two-hour active insulin time). The study investigated off-lab",
      "url": "https://finnhub.io/api/news?id=903017c04ca26ead4bd3f207b6bee76879d74defea2c5244961ea489dee1fdc0"
    }
  },
  {
    "ts": null,
    "headline": "ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?",
    "summary": "ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.",
    "url": "https://finnhub.io/api/news?id=043723e2e7316e5bc3148e938baa108c9b73f44c4bb2c9299ff68dff9d8e81b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767793260,
      "headline": "ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?",
      "id": 138027200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.",
      "url": "https://finnhub.io/api/news?id=043723e2e7316e5bc3148e938baa108c9b73f44c4bb2c9299ff68dff9d8e81b6"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic (MDT) Valuation Check After William Blair Upgrade And Key Hugo And Symplicity Spyral Milestones",
    "summary": "Medtronic (MDT) is back in focus after William Blair upgraded the stock to Outperform, highlighting new product ramps tied to FDA approval for the Hugo surgical system and national coverage for the Symplicity Spyral RDN device. See our latest analysis for Medtronic. The William Blair upgrade comes as Medtronic’s share price edges higher in the short term, with a 1-day share price return of 3.03% and a 7-day share price return of 3.78%. Its 1-year total shareholder return of 29.55% points to...",
    "url": "https://finnhub.io/api/news?id=a00e95857b28aaa8a310ed751a8d0c6f8343e5df60f599fc2a86f1969b0b396c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767769689,
      "headline": "Medtronic (MDT) Valuation Check After William Blair Upgrade And Key Hugo And Symplicity Spyral Milestones",
      "id": 138025916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic (MDT) is back in focus after William Blair upgraded the stock to Outperform, highlighting new product ramps tied to FDA approval for the Hugo surgical system and national coverage for the Symplicity Spyral RDN device. See our latest analysis for Medtronic. The William Blair upgrade comes as Medtronic’s share price edges higher in the short term, with a 1-day share price return of 3.03% and a 7-day share price return of 3.78%. Its 1-year total shareholder return of 29.55% points to...",
      "url": "https://finnhub.io/api/news?id=a00e95857b28aaa8a310ed751a8d0c6f8343e5df60f599fc2a86f1969b0b396c"
    }
  },
  {
    "ts": null,
    "headline": "William Blair Upgrades Medtronic (MDT)",
    "summary": "William Blair Upgrades Medtronic (MDT)",
    "url": "https://finnhub.io/api/news?id=1dcb5e11f96aa105289bf2d1a4376ebb268c4782e1eb67c92fe3a9e99e48e4e0",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767744212,
      "headline": "William Blair Upgrades Medtronic (MDT)",
      "id": 138018178,
      "image": "",
      "related": "MDT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1dcb5e11f96aa105289bf2d1a4376ebb268c4782e1eb67c92fe3a9e99e48e4e0"
    }
  }
]